Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-44

You fail to realise the point
Covid hospitalisations (with severe disease) dropping dramatically around the globe
Some experts say this is likely to continue due to the Omicron (and its subvariant) being more mild and with its dramatic transmissibility likely to engulf the remaining Delta strain which had a higher chance of hospitalisation with severe disease

BIT225 is earmarked by BIT to treat severe disease from Covid

Omicron has reduced BIT225's commercial attractiveness (for Covid) unfortunately...hence the dropping of the share price

BIT love their flashy announcements, which generally are followed by pump and dumps (the trend)

The real news HIV1 trial data in a year from now or perhaps longer...while we wait there will be continuous selling pressure